SEC Company Response from Traws Pharma, Inc. (TRAW) (CIK 0001130598) (TRAW) — Dec 27, 2017
Traws Pharma, Inc. (TRAW) (CIK 0001130598)
Date: Dec. 27, 2017 · CIK: 0001130598 · Accession: 0001104659-17-075210
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221684
Letter
Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18954
December 27, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale
Mary Beth Breslin
Re: Onconova Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 20, 2017
File No. 333-221684
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 9:00 a.m. (Washington, D.C. time) on December 28, 2017, or as soon as practicable thereafter.
ONCONOVA THERAPEUTICS, INC.
By:
/s/ MARK GUERIN
Name:
Mark Guerin
Title:
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm Onconova Therapeutics, Inc. 375 Pheasant Run Newtown, PA 18954 December 27, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Mary Beth Breslin Re: Onconova Therapeutics, Inc. Registration Statement on Form S-3 Filed November 20, 2017 File No. 333-221684 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 9:00 a.m. (Washington, D.C. time) on December 28, 2017, or as soon as practicable thereafter. ONCONOVA THERAPEUTICS, INC. By: /s/ MARK GUERIN Name: Mark Guerin Title: Chief Financial Officer